Maravai LifeSciences $646.9 million secondary offering
We advised the joint book-running managers on the equity offering

Davis Polk advised the joint book-running managers in connection with the $646.9 million secondary offering of 20,700,000 shares of common stock of Maravai LifeSciences Holdings, Inc. by certain selling shareholders, which includes 2,700,000 shares from the full exercise of the underwriters’ option to purchase additional shares. Maravai’s Class A common stock is listed on the Nasdaq Global Select Market under the symbol “MRVI.”

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. Maravai’s products address the key phases of biopharmaceutical development and include complex nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products and products to detect the expression of proteins in tissues of various species. Maravai LifeSciences is headquartered in San Diego, California.

The Davis Polk corporate team included partner Alan F. Denenberg and associate Daniel Reichert. Counsel Kiara L. Rankin and associate Benjamin Helfgott provided tax advice. Partner David R. Bauer and associate Brette L. Trost provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.